{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:53:35Z","timestamp":1781819615852,"version":"3.54.5"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate anatomical and functional outcomes after four monthly intravitreal faricimab injections in White patients with polypoidal choroidal vasculopathy previously treated with other antivascular endothelial growth factor agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The authors retrospectively reviewed medical records and optical coherence tomography (OCT) scans from patients switched to faricimab. Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), OCT biomarkers, and treatment interval extension were analyzed. Ocular and systemic adverse events were recorded as part of routine clinical follow-up to assess treatment tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty-eight eyes were included. BCVA remained stable in 53.57% of eyes, improved by five to nine letters in 17.85% and decreased by more than five letters in 28.57%. Overall, 71.42% maintained or improved BCVA. CRT remained stable in 71.42% of eyes; increased by more than 50\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m in four eyes; and decreased by more than 50\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m in four eyes. Overall, 85.71% of eyes demonstrated stable or reduced CRT after conversion to faricimab. Most eyes showed no changes in OCT biomarkers. Complete resolution of subretinal fluid and intraretinal fluid occurred in 35.71% of cases. Twelve patients (42.85%) were able to have their injection interval extended. No cases of intraocular inflammation, retinal vasculitis, endophthalmitis, or systemic adverse events were observed during the study period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Switching to faricimab resulted in anatomical and functional stability in most previously treated polypoidal choroidal vasculopathy patients and was well-tolerated during the study period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004834","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:00:42Z","timestamp":1773777642000},"page":"1212-1219","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["RESPONSE TO FARICIMAB IN REFRACTORY WHITE POLYPOIDAL CHOROIDAL VASCULOPATHY SWITCHERS"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4349-2941","authenticated-orcid":false,"given":"Giulia","family":"Caruso","sequence":"first","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Oshallah","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios E.","family":"Sepetis","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyashree","family":"Joshi","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kiew","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavan","family":"Bhachech","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1185-6942","authenticated-orcid":false,"given":"Gabriella","family":"De Salvo","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"},{"name":"Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260618","first-page":"1","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV)","volume":"32","author":"Yannuzzi","year":"2012","journal-title":"Retina"},{"key":"R3-20260618","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ceo.13114","article-title":"Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of \u2018expanded spectra\u2019-a review","volume":"46","author":"Dansingani","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"R4-20260618","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","article-title":"Pachychoroid pigment epitheliopathy","volume":"33","author":"Warrow","year":"2013","journal-title":"Retina"},{"key":"R5-20260618","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00006982-199515020-00003","article-title":"Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy","volume":"15","author":"Spaide","year":"1995","journal-title":"Retina"},{"key":"R6-20260618","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ajo.2014.08.025","article-title":"Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy","volume":"158","author":"De Salvo","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R7-20260618","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"key":"R8-20260618","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.4103\/ijo.IJO_975_18","article-title":"Current management strategy of polypoidal choroidal vasculopathy","volume":"66","author":"Ho","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"R9-20260618","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","article-title":"Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results","volume":"156","author":"Oishi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R10-20260618","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ophtha.2013.12.037","article-title":"LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy","volume":"121","author":"Oishi","year":"2014","journal-title":"Ophthalmology"},{"key":"R11-20260618","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R12-20260618","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R13-20260618","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","article-title":"Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy","volume":"165","author":"Cho","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R14-20260618","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1097\/IAE.0000000000001047","article-title":"Angiographic findings of ranibizumab-resistant polypoidal choroidal vasculopathy after switching to a treat-and-extend regimen with intravitreal aflibercept","volume":"36","author":"Azuma","year":"2016","journal-title":"Retina"},{"key":"R15-20260618","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00417-014-2838-5","article-title":"Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"253","author":"Kawashima","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R16-20260618","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/ceo.13602","article-title":"Sorsby fundus dystrophy with polypoidal choroidal vasculopathy: extending TIMP3 phenotypes","volume":"47","author":"Koutresi","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"key":"R17-20260618","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization","volume":"141","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R19-20260618","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye"},{"key":"R20-20260618","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"R21-20260618","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal. faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"R22-20260618","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and- extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"R24-20260618","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/aos.16797","article-title":"Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis","volume":"103","author":"Arnold-Vangsted","year":"2025","journal-title":"Acta Ophthalmol"},{"key":"R25-20260618","doi-asserted-by":"crossref","first-page":"1346322","DOI":"10.3389\/fopht.2023.1346322","article-title":"Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population","volume":"3","author":"Ibrahim","year":"2023","journal-title":"Front Ophthalmol"},{"key":"R26-20260618","first-page":"476","article-title":"Factors associated with success of switching to faricimab for neovascular age-related macular degeneration refractory to intravitreal aflibercept","volume":"14","author":"Machida","year":"2024","journal-title":"Life (Basel)"},{"key":"R27-20260618","first-page":"1859","article-title":"Faricimab for polypoidal choroidal vasculopathy: week 16 results from the phase 3b\/4 SALWEEN trial","volume":"66","author":"Lee","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R28-20260618","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1167\/iovs.13-13111","article-title":"Angiographic features of transgenic mice with increased expression of human serine protease HTRA1 in retinal pigment epithelium","volume":"55","author":"Kumar","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-20260618","doi-asserted-by":"crossref","first-page":"14578","DOI":"10.1073\/pnas.1102853108","article-title":"Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polypoidal choroidal vasculopathy in mice","volume":"108","author":"Jones","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"R30-20260618","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2009.02.012","article-title":"Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy","volume":"148","author":"Cho","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R31-20260618","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ajo.2010.05.035","article-title":"Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab","volume":"150","author":"Stangos","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R32-20260618","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.3390\/ijms231810206","article-title":"HTRA1 regulates subclinical inflammation and activates proangiogenic response in the retina and choroid","volume":"23","author":"Ahamed","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R33-20260618","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00417-021-05445-0","article-title":"Cytokine profiles of macular neovascularization in the elderly based on a classification from a pachychoroid\/drusen perspective","volume":"260","author":"Inoda","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R34-20260618","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/OPTH.S448507","article-title":"Short-term outcomes of 3 monthly intravitreal faricimab on different subtypes of neovascular age-related macular degeneration","volume":"18","author":"Tanaka","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"R35-20260618","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41598-024-52448-y","article-title":"Effect of polyp regression and reduction on treatment efficacy in polypoidal choroidal vasculopathy treated with aflibercept","volume":"14","author":"Sayanagi","year":"2024","journal-title":"Sci Rep"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:01:14Z","timestamp":1781816474000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004834","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}